caa a22 4500 606180370 CHVBK 20210128100805.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s11136-014-0773-x doi (NATIONALLICENCE)springer-10.1007/s11136-014-0773-x Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients [Elektronische Daten] [Hong-Hwa Chen, William Chen, Hsin-Chung Lee, Jen-Kou Lin, Chuan-Yin Fang, Yenn-Hwei Chou, Peng-Chan Lin, Bo-Wen Lin, Chi-Chou Huang, Chung-Hung Yeh, Hsi-Hsien Hsu, Hung-Chang Chen, Wen-Chien Ting, Ming-Chin Yang, Elise Tan] Purpose: The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. Methods: We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics. Results: A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P=0.024; final, P=0.013), appetite loss (mid-term, P<0.0001; final, P=0.001), and fewer side effects from chemotherapy (mid-term, P=0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient]. Conclusions: Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer. Springer International Publishing Switzerland, 2014 Colorectal cancer nationallicence Quality of life nationallicence Societal cost nationallicence Adjuvant treatment nationallicence Chen Hong-Hwa Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan aut Chen William Department of Surgery, China Medical University Hospital, Taichung, Taiwan aut Lee Hsin-Chung Department of Surgery, Cathay General Hospital, Taipei, Taiwan aut Lin Jen-Kou Section of Colon and Rectal Surgery, Taipei Veterans General Hospital, Taipei, Taiwan aut Fang Chuan-Yin Division of Colon and Rectal Surgery, Department of Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan aut Chou Yenn-Hwei Division of Colorectal Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan aut Lin Peng-Chan Department of Internal Medicine, Division of Hematology and Oncology, National Cheng-Kung University Medical Institute and Hospital, Tainan, Taiwan aut Lin Bo-Wen Division of Colon and Rectal Surgery, Department of Surgery, National Cheng-Kung University Medical Institute and Hospital, Tainan, Taiwan aut Huang Chi-Chou Division of Colon and Rectal Surgery, Chuang Shan Medical University Hospital, Taichung, Taiwan aut Yeh Chung-Hung Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan aut Hsu Hsi-Hsien Department of Colorectal Surgery, Mackay Memorial Hospital, Taipei, Taiwan aut Chen Hung-Chang Department of Colorectal Surgery, Changhua Christian Hospital, Changhua, Taiwan aut Ting Wen-Chien Division of Colon and Rectal Surgery, Chuang Shan Medical University Hospital, Taichung, Taiwan aut Yang Ming-Chin Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan aut Tan Elise Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan aut Quality of Life Research Springer International Publishing 24/2(2015-02-01), 473-484 0962-9343 24:2<473 2015 24 11136 https://doi.org/10.1007/s11136-014-0773-x text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11136-014-0773-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chen Hong-Hwa Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan aut NATIONALLICENCE 700 1- Chen William Department of Surgery, China Medical University Hospital, Taichung, Taiwan aut NATIONALLICENCE 700 1- Lee Hsin-Chung Department of Surgery, Cathay General Hospital, Taipei, Taiwan aut NATIONALLICENCE 700 1- Lin Jen-Kou Section of Colon and Rectal Surgery, Taipei Veterans General Hospital, Taipei, Taiwan aut NATIONALLICENCE 700 1- Fang Chuan-Yin Division of Colon and Rectal Surgery, Department of Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan aut NATIONALLICENCE 700 1- Chou Yenn-Hwei Division of Colorectal Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan aut NATIONALLICENCE 700 1- Lin Peng-Chan Department of Internal Medicine, Division of Hematology and Oncology, National Cheng-Kung University Medical Institute and Hospital, Tainan, Taiwan aut NATIONALLICENCE 700 1- Lin Bo-Wen Division of Colon and Rectal Surgery, Department of Surgery, National Cheng-Kung University Medical Institute and Hospital, Tainan, Taiwan aut NATIONALLICENCE 700 1- Huang Chi-Chou Division of Colon and Rectal Surgery, Chuang Shan Medical University Hospital, Taichung, Taiwan aut NATIONALLICENCE 700 1- Yeh Chung-Hung Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan aut NATIONALLICENCE 700 1- Hsu Hsi-Hsien Department of Colorectal Surgery, Mackay Memorial Hospital, Taipei, Taiwan aut NATIONALLICENCE 700 1- Chen Hung-Chang Department of Colorectal Surgery, Changhua Christian Hospital, Changhua, Taiwan aut NATIONALLICENCE 700 1- Ting Wen-Chien Division of Colon and Rectal Surgery, Chuang Shan Medical University Hospital, Taichung, Taiwan aut NATIONALLICENCE 700 1- Yang Ming-Chin Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan aut NATIONALLICENCE 700 1- Tan Elise Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan aut NATIONALLICENCE 773 0- Quality of Life Research Springer International Publishing 24/2(2015-02-01), 473-484 0962-9343 24:2<473 2015 24 11136